Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. reported second-quarter 2026 results and major financing and pipeline milestones. For the three months ended June 30, 2026, the company generated no revenue, incurred research and development expenses of $3.2 million and general and administrative expenses of $1.4 million. Net loss was $7.3 million, or $0.14 per share, compared with $2.7 million, or $0.06 per share, a year earlier, driven in part by a $2.7 million non-cash fair value remeasurement of pre-funded warrants issued in April 2026. As of June 30, 2026, cash and cash equivalents were $11.3 million and restricted cash was $7.1 million.
The company highlighted U.S. FDA alignment on a 12‑month registrational Phase 3 study of EB613 for osteoporosis, with study initiation planned for late 2026 and topline data anticipated in the second half of 2028, to support a New Drug Application. Entera completed an oversubscribed $275.0 million private placement led by BVF Partners L.P., which it expects will fully fund the EB613 Phase 3 program through topline results and anticipated NDA submission and support operations into 2030. IND-enabling studies are ongoing for EB612 for hypoparathyroidism, with an IND filing intended in the first half of 2027, alongside additional oral peptide programs EB618 and an oral GLP‑2 tablet in collaboration with OPKO Health.
Entera Bio Ltd. has a significant shareholder group led by Longitude Venture Partners V, L.P., which is the record owner of 7,843,138 ordinary shares. Based on 172,251,411 ordinary shares outstanding as of July 28, 2026, the filing reports this position as 4.6% of the class for each Reporting Person.
Longitude Capital Partners V, LLC is the general partner of LVPV, and Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCPV; each may be deemed to share voting and dispositive power over these shares, while disclaiming beneficial ownership except to the extent of pecuniary interest. The filing also notes that Seven Fleet may be deemed to beneficially own 7,053,898 ordinary shares, or 4.1%, under certain policies and procedures, though group status and related beneficial ownership are expressly disclaimed.
Entera Bio, Ltd. is reported to have significant ownership by investment funds managed by Seven Fleet Capital Management and by Brian Liu. Seven Fleet Horizon Master Fund is the record owner of 1,960,784 Ordinary Shares, and Seven Fleet Master Fund holds 5,093,114 Ordinary Shares, for an aggregate of 7,053,898 Ordinary Shares that Seven Fleet Capital Management, its general partner, and Brian Liu may be deemed to beneficially own. This stake represents 4.1% of the 172,251,411 Ordinary Shares outstanding as of July 28, 2026, with only shared, not sole, voting and dispositive power reported. The disclosure also notes that Longitude Capital Management and its affiliates may be deemed to beneficially own 7,843,138 Ordinary Shares, or 4.6% of the class, under policies and procedures that could cause them and the Seven Fleet entities to be viewed as a group, while all such parties expressly disclaim group status and certain beneficial ownership.
Biotechnology Value Fund and affiliated entities report beneficial ownership of 17,225,121 ordinary shares of Entera Bio Ltd. (9.99% of outstanding shares), accumulated through significant April and July 2026 financings and related investments using working capital.
In April 2026, Entera completed a private placement of 7,827,789 units for approximately $10.0 million at $1.2775 per unit, each unit comprising one share (or an April pre-funded warrant) and a warrant for 1.5 shares. In July 2026, Entera raised approximately $275.0 million by selling 134,803,910 shares (or July pre-funded warrants) at $2.04 per share, issuing 14,627,893 shares and 11,842,695 July pre-funded warrants to the reporting group.
The investors also hold April and July pre-funded warrants and standard warrants covering tens of millions of shares, subject to 4.99% and 9.99% beneficial ownership blockers that currently restrict exercise. Under the July agreement, the group may designate up to two directors to Enteras board while maintaining specified ownership thresholds and has agreed to support proposals increasing the 2018 equity plan and restoring executive ownership percentages.
Entera Bio Ltd. received a beneficial ownership report from TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC and Chen Yu. The reporting persons disclose beneficial ownership of 12,254,901 ordinary shares of Entera Bio, representing 7.1% of the outstanding ordinary shares, with shared voting and dispositive power over all such shares and no sole voting or dispositive power. The ownership percentage is calculated based on 172,251,449 ordinary shares outstanding, comprising 49,290,234 ordinary shares outstanding as of May 19, 2026 and 122,961,215 ordinary shares issued in a private placement that closed on July 28, 2026. The securities are held of record by TCG Crossover Fund III, L.P., for which TCG Crossover GP III serves as general partner; Chen Yu is the sole managing member of TCG Crossover GP III. Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Entera Bio Ltd. has a new large shareholder group led by Vivo Opportunity entities. Vivo Opportunity, LLC may be deemed to beneficially own 11,817,401 Ordinary Shares, representing 6.9% of Entera Bio’s Ordinary Shares outstanding. These shares are held through Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Co-Invest, L.P., and Vivo Opportunity Co-Invest (Cycle 3), L.P.
Vivo Opportunity Cayman, LLC may be deemed to beneficially own an additional 437,500 Ordinary Shares, or 0.3% of the class, held by Vivo Opportunity Cayman Fund, L.P. The ownership percentages are based on 172,251,411 Ordinary Shares outstanding, which includes 122,961,215 Ordinary Shares issued in a private placement completed on July 28, 2026. Each Vivo entity reports sole voting and dispositive power over its respective holdings.
Entera Bio Ltd. completed a private placement with institutional and accredited investors for 134,803,910 ordinary shares (or pre-funded warrants) at $2.04 per share, raising approximately $275.0 million. On July 28, 2026 it issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants.
The pre-funded warrants are immediately exercisable at an exercise price of NIS 0.0000769 per ordinary share, have no expiration date and include 4.99% or 9.99% beneficial ownership limits, with potential increases up to 19.99%. Net proceeds are intended to support initiation of a phase 3 registrational study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.
Funds affiliated with BVF Partners L.P. obtained rights to designate up to two directors, which step down at 75.0%, 50.0% and 10.0% ownership thresholds, and one designee is expected to serve on the Nominating and Governance Committee. Purchasers agreed to support proposals to increase the 2018 Equity Incentive Plan share reserve and approve executive equity grants restoring pre-transaction beneficial ownership levels. Entera Bio agreed to file a resale registration statement within 30 days of closing and to use reasonable best efforts to have it declared effective.
Entera Bio Ltd. held its 2026 Annual Meeting of Shareholders on July 14, 2026. Shareholders approved an amendment to the 2018 Equity Incentive Plan adding a one-time 2,500,000 Ordinary Shares to the pool available for equity awards. They also approved an Articles Amendment increasing authorized Ordinary Shares from 140,010,000 to 350,000,000.
Shareholders re-elected Sean Ellis, Steven D. Rubin and Geno H. Germano as Class III directors for terms running until the 2029 Annual Meeting. They approved revised non-executive director compensation, several one-time and share-based compensation grants, an advisory say-on-pay proposal, and the appointment of Kesselman & Kesselman as independent auditors for the fiscal year ending December 31, 2026.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that CEO Toledano Miranda Jayne received two grants of stock-settled restricted stock units representing 72,993 and 347,567 ordinary shares on July 14, 2026. The awards were approved by the board on May 7, 2026 and by shareholders on July 14, 2026.
One grant was awarded in lieu of her 2025 annual cash bonus, and the other in lieu of $100,000 of her 2026 base salary. Both RSU grants vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.